Clinical Trial: Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome
Study Status: Completed
Recruit Status: RECRUITING
Condition: Myelodysplastic Syndrome
Study Type: INTERVENTIONAL
Official Title: A Phase Ib/II Study Evaluating Navitoclax After Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Brief Summary:
This phase Ib/II trial tests the safety, side effects, and best dose of navitoclax in combination with venetoclax and decitabine in treating patients with higher risk myelodysplastic syndrome (MDS) that has come back after initial treatment or was not responsive to initial treatment.This study will also look at the effectiveness of the treatment combination and patient's quality of life while on these medications.Navitoclax is an oral drug that works as an inhibitor of the BCL-2 family of proteins, which…
Read more